Enliven Therapeutics, Inc.
- ELVN
- NASDAQ
- Biotechnology
- Kinase Inhibitors
- Small Molecule Cancer Drugs
- Targeted Therapies
$37.32
Today −5.11%Quote Oct 16, 2026, 08:00 PM UTC
−25.72%over the last month
Max drawdown −25.7%From 1-month high −25.7%3 months −27.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$2.73B
Quote Oct 16
Next earnings
Nov 11
Expected, not confirmed
Analyst target
$75.14
+101.3% from here
Floor
$34.70
7.0% below price
Where the price sits
9 analysts
Analyst range, low to high
$65.00$82.00
- Price $37.32
- Resistance $37.84
- Consensus $75.14
The price is right under resistance. Analysts' average target sits about 101% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ELVNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
67